NCT00049374View on ClinicalTrials.gov

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2002

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

oblimersen sodium

DRUG

dexamethasone

DRUG

thalidomide

Trial Locations (2)

10011

St. Vincent's Comprehensive Cancer Center - Manhattan, New York

21201-1592

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Maryland Greenebaum Cancer Center

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT00049374 - Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter